Samjo Management LLC Reduces Stock Position in MDxHealth SA $MDXH

Key Points

• Samjo Management LLC cut its stake in MDxHealth SA by 10.5%, now holding 1,632,068 shares valued at approximately $2.32 million.
• Several institutional investors, including AWM Investment Company and Perkins Capital Management, have recently adjusted their holdings, with AWM increasing its stake by 11.1%.
• MDxHealth reported earnings of ($0.15) per share, missing estimates, and aims for Q2 2025 guidance of -0.150--0.150 EPS.

Samjo Management LLC decreased its position in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) by 10.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,632,068 shares of the company's stock after selling 192,244 shares during the quarter. MDxHealth accounts for about 1.0% of Samjo Management LLC's holdings, making the stock its 27th biggest position. Samjo Management LLC owned about 3.45% of MDxHealth worth $2,318,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. AWM Investment Company Inc. increased its stake in MDxHealth by 11.1% in the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock valued at $11,189,000 after purchasing an additional 471,290 shares in the last quarter. Perkins Capital Management Inc. grew its holdings in MDxHealth by 20.1% in the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after purchasing an additional 198,000 shares during the last quarter. Northern Trust Corp purchased a new position in shares of MDxHealth in the fourth quarter valued at $1,033,000. Renaissance Technologies LLC increased its position in shares of MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after buying an additional 108,000 shares in the last quarter. Finally, Northern Right Capital Management L.P. acquired a new position in shares of MDxHealth during the 4th quarter worth $246,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a research note on Saturday, May 24th. Craig Hallum initiated coverage on shares of MDxHealth in a report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $7.00.

MDxHealth Stock Up 7.2%

MDXH opened at $3.29 on Friday. The firm has a market cap of $155.58 million, a P/E ratio of -3.74 and a beta of 1.41. The business's fifty day simple moving average is $2.42 and its 200 day simple moving average is $1.99. MDxHealth SA has a 52 week low of $1.35 and a 52 week high of $3.29. The company has a quick ratio of 1.92, a current ratio of 1.31 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. The business had revenue of $26.60 million during the quarter, compared to analyst estimates of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, equities research analysts anticipate that MDxHealth SA will post -1.15 EPS for the current fiscal year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

Want to see what other hedge funds are holding MDXH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MDxHealth SA (NASDAQ:MDXH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.